Opus Genetics (IRD)
Develops mutation-specific retinal gene therapies alongside partnered and investigational ophthalmology medicines.
Something off on this page? Send us feedback.
Develops mutation-specific AAV gene therapies for inherited retinal diseases while retaining partnered phentolamine eye-drop economics and APX3330 development. Revenue comes from the Viatris collaboration, while the gene-therapy candidates remain investigational.
Develops a portfolio of mutation-specific AAV gene-therapy programs for inherited retinal diseases, including OPGx-LCA5 and OPGx-BEST1 in human testing, alongside preclinical and pre-IND candidates. The portfolio targets underlying genetic causes of severe retinal disorders and is developed through academic licenses, clinical sites, contract organizations, and partner support.
Retains small-molecule ophthalmology assets from Ocuphire. Viatris commercializes RYZUMVI for reversal of pharmacologically induced mydriasis and funds development activities under its license; phentolamine is also being studied for presbyopia and night-driving impairment, while APX3330 is a post-midstage diabetic-retinopathy asset. All reported revenue comes from the Viatris collaboration, and every gene-therapy candidate remains investigational.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | Oppenheimer | Reiterate | Rating: —Target: — | Target: $20 |
| Sep 9, 2026 | Chardan Capital | Reiterate | Rating: —Target: — | Target: $16 |
| Aug 7, 2026 | RBC Capital | Reiterate | Rating: —Target: $10 | Target: $9 |
| Jul 29, 2026 | Cowen & Co. | Initiate | Rating: — | |
| Jun 23, 2026 | RBC Capital | Initiate | Rating: —Target: — | Target: $10 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $88.8M · Total debt $34.9M · Total assets $93.0M · Shareholders' equity −$13.0M
- Revenue
- $755.0K
- Operating income
- −$16.5M
- Net income
- −$8.1M
No dividends on record.
| Insiders | 11.27% | 9.17M shares | |
|---|---|---|---|
| 15 holders · as of Sep 11, 2026 | |||
| Strategic holders | 4.66% | 3.79M shares | |
| 1 holder · as of May 20, 2026 | |||
| Other | 84.07% | 68.43M shares | |
| remainder | |||
81.40M company shares as of Sep 22, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Perceptive Advisors LLCInstitution | 10.85% | 8.83M | filed May 15, 2026 |
Caligan Partners LPInstitution | 7.46% | 6.08M | filed May 15, 2026 |
Adage Capital Management, L.P.Institution | 7.41% | 6.03M | filed May 13, 2026 |
Balyasny Asset Management L.P.Institution | 6.28% | 5.11M | filed May 15, 2026 |
Nantahala Capital Management, LLCInstitution | 5.95% | 4.84M | filed May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 3, 2026 | Robert E. Gagnon | officer: Chief Financial Officer | −28,000 | $4.54 |
| Jul 23, 2026 | Robert E. Gagnon | officer: Chief Financial Officer | −7,783 | $2.95 |
| Jul 23, 2026 | George Magrath | director, officer: Chief Executive Officer | −9,475 | $2.95 |
| Jul 23, 2026 | Joseph K. Schachle | officer: Chief Operating Officer | −4,644 | $2.94 |
| Jul 23, 2026 | Benjamin R. Yerxa | director, officer: President | −7,429 | $2.97 |
- AbbVie
Marketed presbyopia-drop rival through VUITY.
- LENZ
Commercial presbyopia-drop rival through VIZZ.
- Regeneron
Established injectable alternative in diabetic retinopathy.
- Ocugen
Late-stage modifier gene therapy rival in inherited retinal disease.
- MeiraGTx
LCA gene-therapy developer with a partnered AAV-AIPL1 program.
